C030039L03Rik Activators
C030039L03Rik, a central participant in cellular processes, plays a pivotal role in orchestrating various functions within the cell. While the precise role of C030039L03Rik may display context-dependent variations across cell types and tissues, its overarching function involves [insert specific function of C030039L03Rik]. This protein emerges as a key player in maintaining cellular homeostasis, actively responding to external signals and contributing to the regulation of diverse cellular processes.
The activation of C030039L03Rik is a multifaceted process intricately intertwined with various signaling pathways. Notably, the TGF-β signaling pathway assumes a central role in influencing C030039L03Rik activation indirectly through the inhibition of TGF-β receptors. This intricate modulation within the TGF-β pathway brings about alterations in downstream signaling events, ultimately influencing the expression and function of C030039L03Rik through complex signaling crosstalk. Additionally, the MAPK, PI3K/AKT, JNK, and p38 MAPK pathways contribute to the regulatory mechanisms governing C030039L03Rik. Inhibition of MEK, ERK1/2, PI3K, JNK, and p38 MAPK disrupts downstream events, leading to modifications in the expression and function of C030039L03Rik. This elaborate network of signaling pathways underscores the adaptability and sensitivity of C030039L03Rik to diverse cellular signals, positioning it as a critical hub in the intricate web of cellular regulation and homeostasis. As a key mediator in cellular processes, C030039L03Rik stands at the crossroads of various signaling cascades, actively shaping cellular responses and contributing to the fine-tuned orchestration of cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
TGF-β receptor inhibitor impacting the TGF-β signaling pathway. C030039L03Rik is indirectly activated through TGF-β pathway modulation. By inhibiting TGF-β receptors, downstream events are altered, influencing C030039L03Rik expression and function through intricate signaling crosstalk. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
TGF-β receptor inhibitor disrupting the TGF-β signaling pathway. C030039L03Rik is indirectly activated through TGF-β pathway modulation. By inhibiting TGF-β receptors, interconnected signaling cascades undergo alterations, ultimately influencing C030039L03Rik expression and function. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor impacting the MAPK pathway. C030039L03Rik is indirectly activated as it operates downstream of MAPK. The inhibition of MEK leads to altered expression and function, impacting C030039L03Rik through complex regulatory mechanisms within the MAPK pathway. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
PI3K inhibitor modulating the PI3K/AKT pathway. C030039L03Rik indirectly activates through the PI3K/AKT pathway. By inhibiting PI3K, downstream signaling events are disrupted, impacting C030039L03Rik expression and function through intricate interplay with the PI3K/AKT pathway. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
p38 MAPK inhibitor affecting the p38 MAPK pathway. C030039L03Rik is indirectly activated through p38 MAPK modulation. By inhibiting p38 MAPK, interconnected signaling pathways undergo alterations, ultimately influencing C030039L03Rik expression and function through intricate signaling crosstalk. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK1/2 inhibitor impeding the MAPK pathway. C030039L03Rik indirect activation occurs through MAPK pathway modulation. Inhibiting MEK1/2 disrupts signaling cascades, influencing C030039L03Rik expression and function by altering the dynamics of the MAPK pathway. | ||||||
ERK Inhibitor II, FR180204 | 865362-74-9 | sc-203945 sc-203945A sc-203945B sc-203945C | 1 mg 5 mg 10 mg 50 mg | $110.00 $165.00 $239.00 $942.00 | 45 | |
ERK1/2 inhibitor impacting the MAPK pathway. C030039L03Rik is indirectly activated through MAPK modulation. By inhibiting ERK1/2, downstream signaling events are disrupted, influencing the downstream regulatory elements, ultimately affecting C030039L03Rik expression and function. | ||||||
JNK Inhibitor XVI | 1410880-22-6 | sc-364745 | 10 mg | $357.00 | 5 | |
JNK inhibitor targeting the JNK pathway. C030039L03Rik indirect activation occurs through the JNK pathway. Inhibiting JNK disrupts interconnected signaling pathways, indirectly influencing C030039L03Rik expression and function through complex cellular signaling crosstalk. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
p38 MAPK inhibitor affecting the p38 MAPK pathway. C030039L03Rik is indirectly activated through p38 MAPK modulation. By inhibiting p38 MAPK, interconnected signaling pathways undergo alterations, ultimately influencing C030039L03Rik expression and function through intricate signaling crosstalk. | ||||||